December 11, 2008 11:24 AM
- Text
Novo Nordisk's Liraglutide Logos Leak Out Before Approval
(MoneyWatch)
UPDATE: As BNET predicted, the new Novo Nordisk logos have been suddenly removed from the web. You can still see a Google cache of the page here, and a screen grab here. Novo Nordisk's new diabetes drug, liraglutide, isn't approved by the FDA yet but the company is already working on a set of colorful new logos to promote the drug. You can see them here. The logos all revolve around a theme of five different colors (burgundy, navy, turquoise, slate blue and orange), represented in such things as rain drops, flower petals or apples. Taglines include "Growing our future," "It's time to grow," "Growing together," and "The big picture." (The "It's time to grow" logo, which features apples, looks like a candidate for a copyright infringement claim by Apple Computer.)
The logos were created by design shop Pixel Punch in the UK. I'm going to take a wild guess and suggest that the company is going to receive some angry phonecalls from Novo about releasing their new trademarks w-a-a-ay before the official -- or even legal -- launch date.
Nonethless, Novo may be feeling secure in its daily liraglutide application with the FDA because it has not received one of the new letters requiring drugmakers to do more study of cardiovascular events prior to approval. (BNET readers learned of this new FDA requirement on Nov. 17 and Nov. 25.) However, as this Reuters story says, the company did get a letter regarding once-weekly luraglutide.
Diabetic blogs are already giving the company advice on which logo they should pick. Although this poster doesn't seem to understand that liraglutide is indeed a diabetes drug, the company might do well to road test its work before releasing it. You can learn from confusion in the marketplace.
UPDATE: As BNET predicted, the new Novo Nordisk logos have been suddenly removed from the web. You can still see a Google cache of the page here, and a screen grab here. Novo Nordisk's new diabetes drug, liraglutide, isn't approved by the FDA yet but the company is already working on a set of colorful new logos to promote the drug. You can see them here. The logos all revolve around a theme of five different colors (burgundy, navy, turquoise, slate blue and orange), represented in such things as rain drops, flower petals or apples. Taglines include "Growing our future," "It's time to grow," "Growing together," and "The big picture." (The "It's time to grow" logo, which features apples, looks like a candidate for a copyright infringement claim by Apple Computer.)
The logos were created by design shop Pixel Punch in the UK. I'm going to take a wild guess and suggest that the company is going to receive some angry phonecalls from Novo about releasing their new trademarks w-a-a-ay before the official -- or even legal -- launch date.
Nonethless, Novo may be feeling secure in its daily liraglutide application with the FDA because it has not received one of the new letters requiring drugmakers to do more study of cardiovascular events prior to approval. (BNET readers learned of this new FDA requirement on Nov. 17 and Nov. 25.) However, as this Reuters story says, the company did get a letter regarding once-weekly luraglutide.
Diabetic blogs are already giving the company advice on which logo they should pick. Although this poster doesn't seem to understand that liraglutide is indeed a diabetes drug, the company might do well to road test its work before releasing it. You can learn from confusion in the marketplace.
Latest Now in MoneyWatch
- Insurers respond cautiously to contraceptive plan
- Judge: Legally, breastfeeding not related to pregnancy
- Budget deficit drops to $27 billion in January
- Why the Powerball Jackpot is part of my investment strategy
- Is the new VW Beetle diesel worth the money?
- Consumer sentiment highlights risks to recovery
- Valentine blues? 10 best cities to be single
- December trade deficit widens to $48.8 billion
- Alcatel-Lucent returns to profit in 2011
- 6 things never to say in a performance review
- $26B mortgage deal: Who gets the money?
- Friendly's CEO steps down
- Quarterly loss hits $3.3B at Postal Service
- Greeks rail against cuts as EU demands more
- 6 things you should never share on Facebook
- Make moves now to increase financial aid
- Valentine's Day: 9 places to save
Latest CBS News Headlines
on Facebook Most Discussed Stories
on CBS News
- Fire might have claimed 'Gone with the Wind' items
- Fire might have claimed 'Gone with the Wind' items
- 9/11 drama shown at Berlin film festival
- Syrian general slain in Damascus, regime says
on Facebook Most Discussed Stories
on CBS News






